The Web Ask Dave Taylor

Patient-derived xenografts (PDX) can closely reflect the genetic diversity of human cancer PDX models can enable faster, more robust testing of tumor response to treatment and targeted therapy for patients.

Figure provided by The Jackson Laboratory.

Investigators wishing to access xenografts may choose from a wide variety of human tumor samples.

» Learn More

The development of more effective anti-cancer treatments for patient care can be done in a preclinical setting of the CCXR mouse hospital.

» Learn More


The Cancer Consortium Xenograft Resource (CCXR) is a shared resource to make patient-derived xenografts available for cancer research. It is formed by an agreement between the University of Washington and The Jackson Laboratory.

There are three components:

Seattle Cancer Consortium Partner Institutions:

Seattle Children's .